[1]
|
G. Panos, G. Samonis, V. G. Alexiou, G. A. Kavarnou, G. Charatsis and M. E. Falagas, “Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study,” Current HIV Research, Vol. 6, No. 3, 2008, pp. 257-260.
doi:10.2174/157016208784324976
|
[2]
|
R. P. Walensky, K. A. Freedberg, M. C. Weinstein and A. D. Paltiel, “Cost-Effectiveness of HIV Testing and Treatment in the United States,” Clinical Infectious Diseases, Vol. 45, Suppl. 4, 2007, pp. S248-S254.
doi:10.1086/522546
|
[3]
|
World Health Organization, UNAIDS, UNICEF, “Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector,” 2010.
http://www.who.int/hiv/ pub/2010progressreport/en/ index.html
|
[4]
|
J. A. Aberg, J. E. Gallant, J. Anderson, et al., “Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America,” Clinical Infectious Diseases, Vol. 39, No. 5, 2004, pp. 609-629. doi:10.1086/423390
|
[5]
|
S. M. Hammer, J. J. Eron Jr., P. Reiss, et al., “Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel,” JAMA, Vol. 300, No. 5, 2008, pp. 555-570.
doi:10.1001/jama.300.5.555
|
[6]
|
Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services, “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” 2011.
http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
|
[7]
|
A. M. Geretti, C. Smith, A. Haberl, et al., “Determinants of Virological Failure after Successful Viral Load Suppression in First-Line Highly Active Antiretroviral Therapy,” Antiviral Therapy, Vol. 13, No. 7, 2008, pp. 927-936.
|
[8]
|
C. H. Olsen, J. Gatell, B. Ledergerber, et al., “Risk of AIDS and Death at Given HIV-RNA and CD4 Cell Count, in Relation to Specific Antiretroviral Drugs in the Regimen,” AIDS, Vol. 19, No. 3, 2005, pp. 319-330.
|
[9]
|
C. Cohen, “Low-Level Viremia in HIV-1 Infection: Consequences and Implications for Switching to a New Regimen,” HIV Clinical Trials, Vol. 10, No. 2, 2009, pp. 116-124. doi:10.1310/hct1002-116
|
[10]
|
R. E. Nettles, T. L. Kieffer, R. P. Simmons, et al., “Genotypic Resistance in HIV-1-Infected Patients with Persistently Detectable Low-Level Viremia While Receiving Highly Active Antiretroviral Therapy,” Clinical Infectious Diseases, Vol. 39, No. 7, 2004, pp. 1030-1037.
doi:10.1086/423388
|
[11]
|
N. H. Tobin, G. H. Learn, S. E. Holte, et al., “Evidence That Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of Virus,” Journal of Virology, Vol. 79, No. 15, 2005, pp. 9625-9634. doi:10.1128/JVI.79.15.9625-9634.2005
|
[12]
|
S. A. Van, S. Zhang, P. Reiss, et al., “Immunologic, Virologic, and Clinical Consequences of Episodes of Transient Viremia during Suppressive Combination Antiretroviral Therapy,” Journal of Acquired Immune Deficiency Syndromes, Vol. 48, No. 1, 2008, pp. 104-108.
doi:10.1097/QAI.0b013 e31816a1d4f
|
[13]
|
Y. Mitsuya, M. A. Winters, W. J. Fessel, et al., “HIV-1 Drug Resistance Genotype Results in Patients with Plasma Samples with HIV-1 RNA Levels Less than 75 Copies/mL,” Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 1, 2006, pp. 56-59.
doi:10.1097/01.qai.0000232609.99705.a2
|
[14]
|
T. Doyle and A. M. Geretti, “Low-Level Viraemia on HAART: Significance and Management,” Current Opinion in Infectious Diseases, Vol. 25, No. 1, 2012, pp. 17-25. doi:10.1097/QCO.0b013e32834ef5d9
|
[15]
|
A. C. Karlsson, S. R. Younger, J. N. Martin, et al., “Immunologic and Virologic Evolution during Periods of Intermittent and Persistent Low-Level Viremia,” AIDS, Vol. 18, No. 7, 2004, pp. 981-989.
doi:10.1097/00002030-200404300-00005
|
[16]
|
B. Taiwo, S. Gallien, E. Aga, H. Ribaudo, R. Haubrich, D. R. Kuritzkes and J. J. Eron Jr., “Antiretroviral Drug Resistance in HIV-1-Infected Patients Experiencing Persistent Low-Level Viremia during First-Line Therapy,” Journal of Infectious Diseases, Vol. 204, No. 4, 2011, pp. 515-520. doi:10.1093/infdis/jir353
|
[17]
|
M. Hermankova, S. C. Ray, C. Ruff, et al., “HIV-1 Drug Resistance Profiles in Children and Adults with Viral Load of <50 copies/ml Receiving Combination Therapy,” JAMA, Vol. 286, No. 2, 2001, pp. 196-207.
doi:10.1001/jama.286.2.196
|
[18]
|
M. S. Hirsch, H. F. Gunthard, J. M. Schapiro, et al., “Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel,” Clinical Infectious Diseases, Vol. 47, No. 2, 2008, pp. 266-285. doi:10.1086/589297
|
[19]
|
R. E. Nettles, T. L. Kieffer, P. Kwon, et al., “Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART,” JAMA, Vol. 293, No. 7, 2005, pp. 817-829. doi:10.1001/jama.293.7.817
|
[20]
|
J. L. Sirvent, M. M. Socas, C. H. Calzadilla, A. M. Lirola and M. R. Valls, “Utility of Interrupting Antiretroviral Treatment before HIV Drug Resistance Testing in Patients with Persistently Detectable Low-Level Viremia,” Journal of Acquired Immune Deficiency Syndromes, Vol. 40, No. 1, 2005, pp. 111-113.
doi:10.1097/01.qai.0000174650.33159.22
|
[21]
|
J. Ena, R. F. Ruiz de Apodaca, C. Amador, C. Benito and F. Pasquau, “Net Benefits of Resistance Testing Directed Therapy Compared with Standard of Care in HIV-Infected Patients with Virological Failure: A Meta-Analysis,” Enfermedades Infecciosas y Microbiología Clínica, Vol. 24, No. 4, 2006, pp. 232-237.
doi:10.1016/S0213-005X(06)73768-5
|
[22]
|
J. V. Baker, G. Peng, J. Rapkin, et al., “CD4+ Count and Risk of Non-AIDS Diseases Following Initial Treatment for HIV Infection,” AIDS, Vol. 22, No. 7, 2008, pp. 841-848. doi:10.1097/QAD.0b013e3282f7cb76
|
[23]
|
J. Lawrence, D. L. Mayers, K. H. Hullsiek, et al., “Structured Treatment Interruption in Patients with MultidrugResistant Human Immunodeficiency Virus,” New England Journal of Medicine, Vol. 349, No. 9, 2003, pp. 837-846. doi:10.1056/NEJMoa035103
|
[24]
|
P. K. Lee, T. L. Kieffer, R. F. Siliciano and R. E. Nettles, “HIV-1 Viral Load Blips Are of Limited Clinical Significance,” Journal of Antimicrobial Chemotherapy, Vol. 57, No. 5, 2006, pp. 803-805. doi:10.1093/jac/dkl092
|
[25]
|
D. V. Havlir, R. Bassett, D. Levitan, et al., “Prevalence and Predictive Value of Intermittent Viremia with Combination HIV Therapy,” JAMA, Vol. 286, No. 2, 2001, pp. 171-179. doi:10.1001/jama.286.2.171
|
[26]
|
R. Mohey, L. B. Jorgensen, B. K. Moller, F. T. Black, J. Kjems and N. Obel, “Detection and Quantification of Proviral HIV-1 184 M/V in Circulating CD4(+) T Cells of Patients on HAART with a Viremia Less than 1,000 copies/ml,” Journal of Clinical Virology, Vol. 34, No. 4, 2005, pp. 257-267. doi:10.1016/j.jcv.2005.02.015
|
[27]
|
A. C. Karlsson, S. R. Younger, J. N. Martin, et al., “Immunologic and Virologic Evolution during Periods of Intermittent and Persistent Low-Level Viremia,” AIDS, Vol. 18, No. 7, 2004, pp. 981-989.
doi:10.1097/00002030-200404300-00005
|
[28]
|
S. S. Kaplan, G. Ferrari, T. Wrin, et al., “Longitudinal Assessment of Immune Response and Viral Characteristics in HIV-Infected Patients with Prolonged CD4(+)/ Viral Load Discordance,” AIDS Research and Human Retroviruses, Vol. 21, No. 1, 2005, pp. 13-16.
doi:10.1089/aid.2005.21.13
|
[29]
|
S. G. Deeks, J. N. Martin, E. Sinclair, et al., “Strong Cell-Mediated Immune Responses Are Associated with the Maintenance of Low-Level Viremia in AntiretroviralTreated Individuals with Drug-Resistant Human Immunodeficiency Virus Type 1,” Journal of Infectious Diseases, Vol. 189, No. 2, 2004, pp. 312-321.
doi:10.1086/380098
|
[30]
|
S. G. Deeks, “Durable HIV Treatment Benefit Despite Low-Level Viremia: Reassessing Definitions of Success or Failure,” JAMA, Vol. 286, No. 2, 2001, pp. 224-226.
doi:10.1001/jama.286.2.224
|
[31]
|
A. C. Karlsson, S. R. Younger, J. N. Martin, et al., “Immunologic and Virologic Evolution during Periods of Intermittent and Persistent Low-Level Viremia,” AIDS, Vol. 18, No. 7, 2004, pp. 981-989.
doi:10.1097/00002030-200404300-00005
|
[32]
|
C. M. Vaamonde, D. R. Hoover, K. Anastos, et al., “Factors Associated with Poor Immunologic Response to Virologic Suppression by Highly Active Antiretroviral Therapy in HIV-Infected Women,” AIDS Research and Human Retroviruses, Vol. 22, No. 3, 2006, pp. 222-231.
doi:10.1089/aid.2006.22.222
|
[33]
|
L. Q. Zhang, P. Simmonds, C. A. Ludlam and A. J. Brown, “Detection, Quantification and Sequencing of HIV-1 from the Plasma of Seropositive Individuals and from Factor VIII Concentrates,” AIDS, Vol. 5, No. 6, 1991, pp. 675-681. doi:10.1097/00002030-199106000-00006
|
[34]
|
E. P. Coakley, et al., “HIV Drug Resistance Profiles and Clinical and Virologic Outcomes among HIV-infected Subjects with Stable Detectable Plasma Viral Loads < 1000 copies/mL for at Least 12 Months,” CROI, 2002.
|
[35]
|
M. R. Jordan, M. Kearney, S. Palmer, W. Shao, F. Maldarelli, E. P. Coakley, C. Chappey, C. Wanke and J. M. Coffin, “Comparison of Standard PCR/Cloning to Single Genome Sequencing for Analysis of HIV-1 Populations,” Journal of Virological Methods, Vol. 168, No. 1-2, 2010, pp. 114-120. doi:10.1016/j.jviromet.2010.04.030
|
[36]
|
R. Chenna, H. Sugawara, T. Koike, et al., “Multiple Sequence Alignment with the Clustal Series of Programs,” Nucleic Acids Research, Vol. 31, No. 13, 2003, pp. 3497-3500. doi:10.1093/nar/gkg500
|
[37]
|
BioEdit, 2012.
http://www.mbio.ncsu.edu/bioedit/bioedit.html
|
[38]
|
Mega 3.0, 2012. http://www.megasoftware.net
|
[39]
|
T. F. Liu and R. W. Shafer, “Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation,” Clinical Infectious Diseases, Vol. 42, No. 11, 2006, pp. 1608-1618. doi:10.1086/503914
|
[40]
|
I. Kousignian, S. Abgrall, S. Grabar, et al., “Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency,” Clinical Infectious Diseases, Vol. 46, No. 2, 2008, pp. 296-304.
doi:10.1086/524753
|
[41]
|
S. Palmer, M. Kearney, F. Maldarelli, et al., “Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis,” Journal of Clinical Microbiology, Vol. 43, No. 1, 2005, pp. 406-413.
doi:10.1128/JCM.43.1.406-413.2005
|
[42]
|
Y. Mitsuya, M. A. Winters, W. J. Fessel, et al., “HIV-1 Drug Resistance Genotype Results in Patients with Plasma Samples with HIV-1 RNA Levels Less than 75 copies/mL,” Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 1, 2006, pp. 56-59.
doi:10.1097/01.qai.0000232609.99705.a2
|